SLC5A2 and diabetes mellitus: To simulate glucose starvation in a clinically relevant manner, we employed canagliflozin, an anti-diabetes drug known for inhibiting sodium-glucose transport protein 2 (SGLT2), effectively reducing glucose intake by cells [17].